Compugen Ltd. (NASDAQ:CGEN) stock observed trading -39.22% off 52-week high price. On the other end, the stock has been noted 184.98% away from low price over the last 52-weeks. The stock disclosed a move of -3.50% away from 50 day moving average and 48.10% away from 200 day moving average. Moving closer, we can see that shares have been trading -17.81% off 20-day moving average. It has market cap of $734.59M.
On March 17, 2020, Compugen Ltd. (NASDAQ:CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, notified the closing of its previously announced underwritten public offering of 8,333,334 ordinary shares at a price to the public of $9.00 per share. The gross proceeds to Compugen from the offering were approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Compugen. In addition, Compugen has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 ordinary shares, at the public offering price less underwriting discounts and commissions, which has not yet been exercised. The offering closed on March 16, 2020.
SVB Leerink and Stifel acted as joint bookrunning managers for the offering. SunTrust Robinson Humphrey acted as lead manager for the offering and Oppenheimer & Co. acted as co-manager for the offering.
The Israel based company Compugen Ltd. moved with change of 7.61% to $7.78 with the total traded volume of 1363822 shares in recent session versus to an average volume of 756.26K. The stock was observed in the 5 days activity at -33.16%. The one month performance of stock was -13.75%. CGEN’s shares are at 37.70% for the quarter and driving a 104.74% return over the course of the past year and is now at 30.54% since this point in 2018. Right now the stock beta is 1.69. The average volatility for the week and month was at 14.98% and 11.43% respectively. There are 94.42M shares outstanding and 67.78M shares are floated in market.